These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14667473)

  • 1. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):275-98. PubMed ID: 14667473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):201-24. PubMed ID: 12480298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans.
    Walton K; Dorne JL; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):261-74. PubMed ID: 14667472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human variability in glucuronidation in relation to uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2001 Dec; 39(12):1153-73. PubMed ID: 11696390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL; Walton K; Slob W; Renwick AG
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation).
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Mar; 42(3):397-421. PubMed ID: 14871582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.
    Gross AS; McLachlan AJ; Minns I; Beal JB; Tett SE
    Br J Clin Pharmacol; 2001 Jun; 51(6):547-55. PubMed ID: 11422014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human variability in hepatic and renal elimination: implications for risk assessment.
    Dorne JL
    J Appl Toxicol; 2007; 27(5):411-20. PubMed ID: 17497760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.
    Jansat JM; Costa J; Salvà P; Fernandez FJ; Martinez-Tobed A
    J Clin Pharmacol; 2002 Dec; 42(12):1303-10. PubMed ID: 12463724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the renal excretion mechanisms of cefadroxil.
    Granero L; Gimeno MJ; Torres-Molina F; Chesa-Jiménez J; Peris JE
    Drug Metab Dispos; 1994; 22(3):447-50. PubMed ID: 8070323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic process: does the site of drug action? Excretion of drugs].
    Carrillo Norte JA
    Rev Enferm; 2011 Sep; 34(9):24-31. PubMed ID: 22013710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessment of the single intravenous injection method with inulin for measurement of the glomerular filtration rate in man.
    Prescott LF; Freestone S; McAuslane JA
    Clin Sci (Lond); 1991 Feb; 80(2):167-76. PubMed ID: 1848170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal interaction between itraconazole and cimetidine.
    Karyekar CS; Eddington ND; Briglia A; Gubbins PO; Dowling TC
    J Clin Pharmacol; 2004 Aug; 44(8):919-27. PubMed ID: 15286096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2001 Jul; 39(7):681-96. PubMed ID: 11397515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.
    Blonde L; Wehmann RE; Steiner AL
    J Clin Invest; 1974 Jan; 53(1):163-72. PubMed ID: 4357610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ceftizoxime.
    Gundert-Remy U; Hildebrandt R; Stiehl A; Schlegel P
    Eur J Clin Pharmacol; 1985; 28(4):463-7. PubMed ID: 3861322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.